AARD Quote, Financials, Valuation and Earnings

GE HealthCare Technologies has a net margin of -- compared to Aardvark Therapeutics's net margin of 11.81%. Aardvark Therapeutics's return on equity of -- beat GE HealthCare Technologies's return on equity of 25.89%.

Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 193.57%. On the other hand GE HealthCare Technologies has an analysts' consensus of $87.25 which suggests that it could grow by 23.76%. Given that Aardvark Therapeutics has higher upside potential than GE HealthCare Technologies, analysts believe Aardvark Therapeutics is more attractive than GE HealthCare Technologies.

Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GE HealthCare Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GE HealthCare Technologies offers a yield of 0.18% to investors and pays a quarterly dividend of $0.04 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. GE HealthCare Technologies pays out 2.76% of its earnings as a dividend. GE HealthCare Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Aardvark Therapeutics quarterly revenues are --, which are smaller than GE HealthCare Technologies quarterly revenues of $4.8B. Aardvark Therapeutics's net income of -- is lower than GE HealthCare Technologies's net income of $564M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while GE HealthCare Technologies's PE ratio is 14.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 1.63x for GE HealthCare Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -- compared to Aardvark Therapeutics's net margin of 21.68%. Aardvark Therapeutics's return on equity of -- beat Eli Lilly and's return on equity of 78.25%.

Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 193.57%. On the other hand Eli Lilly and has an analysts' consensus of $981.63 which suggests that it could grow by 30.63%. Given that Aardvark Therapeutics has higher upside potential than Eli Lilly and, analysts believe Aardvark Therapeutics is more attractive than Eli Lilly and.

Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Aardvark Therapeutics quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Aardvark Therapeutics's net income of -- is lower than Eli Lilly and's net income of $2.8B. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 61.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 13.85x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Pliant Therapeutics has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Pliant Therapeutics's return on equity of --.

Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 193.57%. On the other hand Pliant Therapeutics has an analysts' consensus of $12.58 which suggests that it could grow by 761.87%. Given that Pliant Therapeutics has higher upside potential than Aardvark Therapeutics, analysts believe Pliant Therapeutics is more attractive than Aardvark Therapeutics.

Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pliant Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pliant Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Pliant Therapeutics pays out -- of its earnings as a dividend.

Aardvark Therapeutics quarterly revenues are --, which are smaller than Pliant Therapeutics quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Pliant Therapeutics's net income of -$49.7M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Pliant Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 17.58x for Pliant Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Soleno Therapeutics has a net margin of -- compared to Aardvark Therapeutics's net margin of --. Aardvark Therapeutics's return on equity of -- beat Soleno Therapeutics's return on equity of --.

Aardvark Therapeutics has a consensus price target of $31.50, signalling upside risk potential of 193.57%. On the other hand Soleno Therapeutics has an analysts' consensus of $111.00 which suggests that it could grow by 45.06%. Given that Aardvark Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Aardvark Therapeutics is more attractive than Soleno Therapeutics.

Aardvark Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Soleno Therapeutics has a beta of -2.668, suggesting its less volatile than the S&P 500 by 366.818%.

Aardvark Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Soleno Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aardvark Therapeutics pays -- of its earnings as a dividend. Soleno Therapeutics pays out -- of its earnings as a dividend.

Aardvark Therapeutics quarterly revenues are --, which are smaller than Soleno Therapeutics quarterly revenues of --. Aardvark Therapeutics's net income of -- is lower than Soleno Therapeutics's net income of -$43.8M. Notably, Aardvark Therapeutics's price-to-earnings ratio is -- while Soleno Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aardvark Therapeutics is -- versus 4,157.26x for Soleno Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.